Fever after @entity583 in @entity1 treated with intravenous XXXX or placebo.

@entity1 @entity6839 @entity908 @entity1188 @entity583
Body temperature was studied in 65 @entity1 admitted to hospital within four hours of the onset of symptoms of @entity583 . Thirty three @entity1 had been randomly assigned to intravenous @entity6839 treatment and 32 to placebo treatment. @entity1188 evolution was assessed by continuous vectorcardiography and @entity908 kinase release. Maximum and mean temperatures during the first eight days were significantly lower in the @entity6839 group, who were discharged from hospital one day earlier. Eight @entity1 in the placebo group had temperatures of greater than 39 degrees compared with one in the @entity6839 group. Both the mean temperature and the maximum temperature correlated significantly with indices of @entity1188 size and ischaemic area as estimated by cumulative @entity908 kinase release, QRS vector difference, and ST vector magnitude. The results were consistent with the view that reduction of @entity1188 size may partly explain the reduced pyrexial response after @entity6839 treatment. Other mechanisms are probably also involved in larger @entity1188 . Because high fever has detrimental haemodynamic effects in @entity583 , reduction of this response may be beneficial. The results support the early use of beta adrenoceptor blockade in @entity583 .
